# US 2012/0252745 A1 · Novobiocin analogues having modified sugar moieties

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252745 A1
- Document ID: US20120252745A1
- Status: Published application
- Kind: A1
- Application number: 13/202,382
- Filed: 2010-02-19
- Published: 2012-10-04
- Earliest claimed: 2004-11-03
- Assignees: University of Kansas
- Inventors: Brian S. J. Blagg; Huiping Zhao; Alison Catherine Donnelly
- Web page: https://patentgrep.com/patent/US20120252745A1

## CPC

- C07D 407/12: linked by a chain containing hetero atoms as chain links
- A61P 35/00: Antineoplastic agents
- C07D 487/14: Ortho-condensed systems
- C07H 19/00: Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides ; Anhydro-derivatives thereof
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.

## Claims

### Claim 1

A compound according to Formula I:
wherein:
R1 is —NHCOR″, where R″ is a C1-C4 alkyl, aryl or heterocyclic group, each optionally substituted with one or more hydroxy, nitro, amino, alkyl, alkenyl, aryl, alkoxy or halo groups;
X9 is —O-alkyl, —O-alkylamino, —O-cycloalkyl, —O—(CO)-alkyl, —O—(CO)-cycloalkyl, —O—(CH2)n-pyridinyl, —O—(CH2)n-piperidinyl, —O—(CH2)n-pyrrolino, or —O—(CH2)n-pyrrolidinyl, each substituted with one or more amino, amido, alkyl, alkoxy, halo, pyrrolidinyl, or hydroxyl groups; and where n is 0, 1 2 or 3; or —O-mono-hydroxylated furanose, —O-dihydroxylated furanose, —O-mono-hydroxylated pyranose, —O-dihydroxylated pyranose, —O-trihydroxylated pyranose, —O-mono-hydroxylatedoxepinose, —O-dihydroxylated oxepinose, —O-azasugar, —O-acyl, ester, amino, amido, carbamate, phosphate ester, tosylate or mesylate; or X9 is —OH provided that R″ is not of the structure:
X is H, nitrile, halo, amino, amido, C1-C4 alkyl or alkoxy; and
Y is H, amido, ester, amino, C1-C4 alkyl or alkoxy; or
a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein X9 is —O-alkyl, —O-alkylamino, —O-cycloalkyl, —O—(CO)-alkyl, —O—(CO)-cycloalkyl, —O—(CH2)n-pyridinyl, —O—(CH2)n-piperidinyl, —O—(CH2)n-pyrrolino, or —O—(CH2)n-pyrrolidinyl, each optionally substituted with one or more amino, amido alkyl, halo, alkoxy, or hydroxyl groups.

### Claim 3 (depends on 1)

The compound of claim 1 wherein X9 is

### Claim 4 (depends on 1)

The compounds of claim 1 wherein R1 is —NHCOCH3.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R″ is an aryl group selected from:
wherein R24 and R25 are independently H, C1-C4 alkyl, hydroxy or alkoxy; and
R33 is H, C1-C4 alkyl, C1-C4 alkylamino, —(CO)—C1-C4 alkyl, or piperidinyl, each optionally substituted with C1-C4 alkyl; or
R″ is a heterocyclic group:
wherein R31 is H, halo, C1-C4 alkyl, hydroxy or alkoxy; and R32 is H or C1-C4 alkyl.

### Claim 6 (depends on 5)

The compound of claim 5 wherein R″ is an aryl group:

### Claim 7 (depends on 6)

The compound of claim 6 in which the compound is selected from the group consisting of:

### Claim 8 (depends on 5)

The compound of claim 5 wherein R″ is aryl according to:
wherein R33 is H, —CH3, —COCH3, —CH2CH2N(CH3)2, —CH2CH2CH2N(CH3)2, or

### Claim 9 (depends on 8)

The compound of claim 8 selected from the group consisting of:
4-(8-Methyl-7-(1-methylpiperidin-4-yloxy)-2-oxo-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl)phenyl acetate (29a, KU-397);
4-(8-Methyl-7-(1-methylpiperidin-3-yloxy)-2-oxo-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl)phenyl acetate (29c, KU-417);
4-(7-(2-(Dimethylamino)ethoxy)-8-methyl-2-oxo-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl)phenyl acetate (29e, KU-421);
4-(7-(3-(Dimethylamino)propoxy)-8-methyl-2-oxo-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl)phenyl acetate (29f, KU-406);
4-(8-methyl-2-oxo-7-(piperidin-4-yloxy)-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl)phenyl acetate (30b, KU-415);
4-(8-methyl-2-oxo-7-(piperidin-3-yloxy)-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl)phenyl acetate (30d, KU-419);
4-(8-methyl-7-(2-(methylamino)ethoxy)-2-oxo-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl)phenyl acetate (30g, KU-423);
4-Hydroxy-N-(8-methyl-7-(1-methylpiperidin-4-yloxy)-2-oxo-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide (31a, KU-398);
4-Hydroxy-N-(8-methyl-2-oxo-7-(piperidin-4-yloxy)-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide (31b, KU-416);
4-Hydroxy-N-(8-methyl-7-(1-methylpiperidin-3-yloxy)-2-oxo-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide (31c, KU-418);
4-Hydroxy-N-(8-methyl-2-oxo-7-(piperidin-3-yloxy)-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide (31d, KU-420);
N-(7-(2-(Dimethylamino)ethoxy)-8-methyl-2-oxo-2H-chromen-3-yl)-4-hydroxy-3-(3-methylbut-2-enyl)benzamide (31e, KU-422);
N-(7-(3-(Dimethylamino)propoxy)-8-methyl-2-oxo-2H-chromen-3-yl)-4-hydroxy-3-(3-methylbut-2-enyl)benzamide (31f, KU-407);
4-Hydroxy-N-(8-methyl-7-(2-(methylamino)ethoxy)-2-oxo-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide (31g, KU-424);
N-(7-((2R,3R,4R)-3,4-dihydroxytetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-4-hydroxy-3-(3-methylbut-2-enyl)benzamide (16a, KU-425);
N-(7-((2S,3R,4R)-3,4-dihydroxytetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-4-hydroxy-3-(3-methylbut-2-enyl)benzamide (16b, KU-426);
4-Hydroxy-N-(7-((2R,3R)-3-hydroxytetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide (17a, KU-247);
4-Hydroxy-N-(7-((2S,3R)-3-hydroxytetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide (17b, KU-428);
4-Hydroxy-N-(7-((2S,4R)-4-hydroxytetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide (18a, KU-429);
4-Hydroxy-N-(7-((2R,4R)-4-hydroxytetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)-3-(3-methylbut-2-enyl)benzamide (18b, KU-430);
4-(7-((2S,3S,4S)-3,4-Dihydroxytetrahydrofuran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl)phenyl acetate (19, KU-431);
4-(7-((2S,4R)-4-Hydroxytetrahydrofuran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl)phenyl acetate (20a, KU-432); and
4-(7-((2R,4R)-4-Hydroxytetrahydrofuran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl)phenyl acetate (20b, KU-433).

### Claim 10 (depends on 8)

The compound of claim 8:

### Claim 11 (depends on 5)

The compound of claim 5 wherein R″ is a heterocyclic group according to:
wherein R31 is H, halo, or alkoxy; and R32 is H or alkyl.

### Claim 12 (depends on 11)

The compound of claim 11:
wherein
X is H or —OCH3;
Y is —CH3 or —OCH3;
R31 is H, Cl, —CH2CH2N(CH3)2, —CH2CH2CH2N(CH3)2, —OCH3, or
R32 is H or —CH3; and
R is selected from the group consisting of:

### Claim 13 (depends on 12)

The compound of claim 12:

### Claim 14 (depends on 6)

The compound of claim 6:
wherein
X is H or —OCH3;
Y is —CH3 or —OCH3; and
R is selected from the group consisting of: H, —COCH3, mesylate, tosylate, —CONH2, —CONHCH3, —CON(CH3)2, —PO(OCH3)2, —COCH3,

### Claim 15 (depends on 14)

The compound of claim 14:

### Claim 16 (depends on 1)

A pharmaceutical composition for the treatment of cancer in a patient in need thereof, the composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 1)

A method of treating cancer in a patient in need thereof, the method comprising administering a therapeutically effective amount of a compound of claim 1.
